FDA wants precaution on Singulair, sister meds

FDA wants some allergy and asthma drugs to come with a new warning of potential psychiatric problems. In an announcement Friday, the agency said it had asked drugmakers to add cautionary language to the labels of Singulair (Merck), Accolate (AstraZeneca), and Zyflo/Zyflo CR (Cornerstone Therapeutics). Not as serious as an actual "warning," the precaution would disclose post-marketing reports of psych problems, some of them severe.

In clinical trials of the drugs, known as leukotrine modifiers, psychiatric side effects were uncommon, FDA said. But the studies weren't designed to evaluate psych issues, so the data are limited the agency said. Post-approval, the agency has received reports of psychiatric problems--from agitation and aggression to suicidal thinking and even suicide. Some of the reports "included clinical details consistent with a drug-induced effect," the FDA noted in its statement.

Responding to the FDA request, Merck said it has already included psychiatric side-effect reports in the post-marketing section of Singulair's label. But the drugmaker said it would work with the FDA to include a precaution about those risks.

- read the FDA release
- check out Merck's response
- see the story from Reuters

Webinar

Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.